Effect of naloxegol on opioid-induced esophageal motility disorder

Authors

Crista Ulteig, Advocate Aurora HealthFollow
Kristin Ciezki, Advocate Aurora HealthFollow
Megan Jacobson, Advocate Aurora HealthFollow
Maharaj Singh, Advocate Aurora HealthFollow
Tarun Sharma, Advocate Aurora HealthFollow

Recommended Citation

Ulteig C, Ciezki K, Jacobson M, Sigh M, Sharma T. Effect of Naloxegol on Opioid-Induced Esophageal Motility Disorder. ACG Case Rep J. 2022;9(1):e00723. Published 2022 Jan 25. doi:10.14309/crj.0000000000000723

Affiliations

Advocate Aurora Health Department of Gastroenterology and Hepatology, Advocate Aurora Research Institute

Abstract

Opioid effects on lower gastrointestinal motility are well documented, and increasing attention is being paid to their effect on esophageal motility. Naloxegol is a µ-opioid receptor antagonist that is used for opioid-induced constipation, but its impact on esophageal motility has not been well documented. We report a case series of 3 patients with coexisting esophageal dysmotility and constipation on chronic opioids that improved both symptoms after starting naloxegol. Based on these observational studies, we propose that formal studies be conducted to assess the effect of naloxegol on opioid-induced esophageal dysmotility.

Type

Article

PubMed ID

35097149